Omega Therapeutics, Inc. logo

Omega Therapeutics, Inc. (OMGA)

Market Closed
11 Jul, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
0. 07
-0.02
-23.5%
$
7.9M Market Cap
- P/E Ratio
0% Div Yield
725,308 Volume
-1.15 Eps
$ 0.09
Previous Close
Day Range
0.06 0.09
Year Range
0.01 2.15
Want to track OMGA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

OMGA closed Friday lower at $0.07, a decrease of 23.5% from Thursday's close, completing a monthly increase of 116.28% or $0.04. Over the past 12 months, OMGA stock lost -91.55%.
OMGA is not paying dividends to its shareholders.
The last earnings report, released on Jun 20, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.01%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).

OMGA Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
Omega Pacific Reports Its Final Drill Hole Yielding Multiple Zones of Mineralization at Its Williams Property

Omega Pacific Reports Its Final Drill Hole Yielding Multiple Zones of Mineralization at Its Williams Property

VANCOUVER, BC / ACCESSWIRE / December 4, 2024 / Omega Pacific Resources Inc. (CSE:OMGA)(OTCQB:OMGPF)(FSE:Q0F) ("Omega Pacific" or the "Company") is pleased to announce final drill results from its 2024 drill program at the Williams Property in British Columbia's Golden Horseshoe. Drill hole WM24-03 returned multiple zones of gold mineralization with local high grades west of discovery hole WM22-02 (ext) (Figure 1).

Accesswire | 7 months ago
Omega Pacific Announces 2024 Work Program Results From Its Lekcin Property

Omega Pacific Announces 2024 Work Program Results From Its Lekcin Property

VANCOUVER, BC / ACCESSWIRE / November 19, 2024 / Omega Pacific Resources Inc. (CSE:OMGA)(OTCQB:OMGPF)(FSE:Q0F) ("Omega Pacific" or the "Company") is pleased to announce results from its field work program at its Lekcin Property, located 120 km east of Vancouver. Background The Lekcin Property (or the "Property") consists of six Mineral Titles Online (MTO) claims that are under option to the Company.

Accesswire | 7 months ago
Omega Therapeutics, Inc. (OMGA) Reports Q3 Loss, Tops Revenue Estimates

Omega Therapeutics, Inc. (OMGA) Reports Q3 Loss, Tops Revenue Estimates

Omega Therapeutics, Inc. (OMGA) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.40 per share a year ago.

Zacks | 8 months ago

Omega Therapeutics, Inc. Dividends

OMGA is not paying dividends to its shareholders.

Omega Therapeutics, Inc. Earnings

20 Jun 2025 Date
-
Cons. EPS
-
EPS
15 Nov 2024 Date
-
Cons. EPS
-
EPS
6 Aug 2024 Date
-
Cons. EPS
-
EPS
20 Jun 2024 Date
-
Cons. EPS
-
EPS
6 Jun 2024 Date
-
Cons. EPS
-
EPS
OMGA is not paying dividends to its shareholders.
20 Jun 2025 Date
-
Cons. EPS
-
EPS
15 Nov 2024 Date
-
Cons. EPS
-
EPS
6 Aug 2024 Date
-
Cons. EPS
-
EPS
20 Jun 2024 Date
-
Cons. EPS
-
EPS
6 Jun 2024 Date
-
Cons. EPS
-
EPS

Omega Therapeutics, Inc. (OMGA) FAQ

What is the stock price today?

The current price is $0.07.

On which exchange is it traded?

Omega Therapeutics, Inc. is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is OMGA.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 7.9M.

Has Omega Therapeutics, Inc. ever had a stock split?

No, there has never been a stock split.

Omega Therapeutics, Inc. Profile

Biotechnology Industry
Healthcare Sector
Kaan Certel CEO
NASDAQ (NGS) Exchange
68217N105 Cusip
US Country
93 Employees
- Last Dividend
- Last Split
30 Jul 2021 IPO Date

Overview

Omega Therapeutics, Inc. is a pioneering force in the field of biotechnology, focusing on the clinical-stage development of novel therapies. Founded in 2016 and based in Cambridge, Massachusetts, the company has dedicated itself to leveraging its proprietary OMEGA platform. This cutting-edge platform targets the control of key epigenetic processes, aiming to address the underlying causes of various diseases by modifying gene expression without changing the DNA sequence itself. Through this innovative approach, Omega Therapeutics seeks to revolutionize the treatment landscape for a multitude of conditions.

Products and Services

  • OTX-2002 - Developed for treating hepatocellular carcinoma, this product is a testament to Omega Therapeutics' commitment to targeting serious and difficult-to-treat cancers through its innovative epigenetic modulation techniques.

  • OTX-2101 - Aiming at non-small cell lung cancer, OTX-2101 represents another facet of the company's focus on utilizing epigenetic controllers to manage cancer. This development underscores the versatility of the company's platform in addressing various types of malignancies.

  • Omega Epigenomic Controllers (OEC) - Designed for a variety of indications including inflammatory lung diseases (such as neutrophilic asthma and acute respiratory distress syndrome), dermatological conditions, oncology, and rheumatological diseases. The OECs embody Omega Therapeutics' ambition to tackle a broad spectrum of diseases by rectifying aberrant gene expression.

  • OEC candidates for idiopathic pulmonary fibrosis - Extending their epigenetic innovations to fibrotic diseases, these candidates are being developed to target the fibrosis and scarring in the lungs characteristic of idiopathic pulmonary fibrosis, further exemplifying the company's versatile approach to disease management.

  • Liver Regeneration Medicines - Reflecting the breadth of Omega Therapeutics' portfolio in regenerative medicine, these products aim to harness the power of epigenetic modulation for liver regeneration, offering new hope for liver disease patients.

  • OEC candidates for diabetes and other conditions to treat corneal epithelial injury - Highlighting the company's foray into ophthalmological and metabolic diseases, these candidates are designed to utilize epigenetic controllers to address corneal injuries, showcasing the potential breadth of the OMEGA platform's applications.

  • OEC candidates for the treatment of alopecia - Addressing the dermatological condition characterized by non-scarring hair loss, these candidates aim to provide novel treatments for alopecia, further diversifying Omega Therapeutics’ therapeutic offerings.

Contact Information

Address: 20 Acorn Park Drive
Phone: 617 949 4360